Market Cap 1.81B
Revenue (ttm) 300,000.00
Net Income (ttm) -269.95M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -89,983.33%
Debt to Equity Ratio 0.04
Volume 1,491,857
Avg Vol 999,962
Day's Range N/A - N/A
Shares Out 81.67M
Stochastic %K 34%
Beta 0.49
Analysts Strong Sell
Price Target $39.73

Company Profile

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company's product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 272 4600
Fax: 617 272 4601
Address:
221 Crescent Street, Suite 401, Waltham, United States
Tdorsey1776
Tdorsey1776 Oct. 24 at 1:13 PM
$VRDN Ready to rock and roll in 2026+
0 · Reply
notreload_ai
notreload_ai Oct. 22 at 4:07 PM
$VRDN raised ∼$251.4M by selling 11.4M shares at $22. Funds will launch veligrotug/VRDN-003, drugs for Thyroid Eye Disease (TED). The offering was priced at an 8.4% discount. https://investors.viridiantherapeutics.com/news/news-details/2025/Viridian-Therapeutics-Announces-Pricing-of-251-Million-Public-Offering-of-Shares-of-Common-Stock/default.aspx
0 · Reply
Butch44
Butch44 Oct. 22 at 3:59 PM
$VRDN don't understand this after the financing deal. ...
1 · Reply
Bondra
Bondra Oct. 22 at 2:48 PM
$VRDN So tempting to sell my CRNX for this gem (now flush with cash 💰)
0 · Reply
aliliimr
aliliimr Oct. 22 at 2:47 PM
$VRDN was waiting for buyout but got this 😀 out for now but will get back if it gets at 19.5 as that was my average :)
0 · Reply
Tdorsey1776
Tdorsey1776 Oct. 22 at 2:04 PM
$VRDN There's a ludicrous amount of money sloshing around
0 · Reply
CDMO
CDMO Oct. 22 at 1:50 PM
$VRDN perfect timing 🫡@CH_Expat
1 · Reply
DonCorleone77
DonCorleone77 Oct. 22 at 12:50 PM
$VRDN Viridian Therapeutics 11.425M share Spot Secondary priced at $22.00
0 · Reply
Pika_Capital
Pika_Capital Oct. 21 at 9:57 PM
$VRDN lol. Offering after recent financial deal. Someone must be wanting to buy tons of shares or these guys just want to sit on huge pile of cash regardless. Tomorrow should be interesting
1 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 1:33 PM
Oppenheimer has adjusted their stance on Viridian Therapeutics ( $VRDN ), setting the rating to Outperform with a target price of 32 → 36.
0 · Reply
Latest News on VRDN
Viridian Therapeutics: The Song Remains The Same

Jun 9, 2025, 6:18 PM EDT - 4 months ago

Viridian Therapeutics: The Song Remains The Same


Viridian Therapeutics: A Clearer Picture Emerges (Rating Upgrade)

Dec 17, 2024, 12:41 PM EST - 11 months ago

Viridian Therapeutics: A Clearer Picture Emerges (Rating Upgrade)


Viridian Therapeutics' Superior Prospects Make It A Buy

Oct 23, 2024, 4:02 PM EDT - 1 year ago

Viridian Therapeutics' Superior Prospects Make It A Buy


3 Small Biotech Stocks With The 'Big Mo' Right Now

Sep 19, 2024, 12:54 PM EDT - 1 year ago

3 Small Biotech Stocks With The 'Big Mo' Right Now

AUPH CORT


Top 3 Health Care Stocks You May Want To Dump This Quarter

Jul 30, 2024, 10:13 AM EDT - 1 year ago

Top 3 Health Care Stocks You May Want To Dump This Quarter

CPRX VRNA


3 Biotech Names With Potential Catalysts By Year End

Jul 29, 2024, 3:32 PM EDT - 1 year ago

3 Biotech Names With Potential Catalysts By Year End

CADL RCKT


Tdorsey1776
Tdorsey1776 Oct. 24 at 1:13 PM
$VRDN Ready to rock and roll in 2026+
0 · Reply
notreload_ai
notreload_ai Oct. 22 at 4:07 PM
$VRDN raised ∼$251.4M by selling 11.4M shares at $22. Funds will launch veligrotug/VRDN-003, drugs for Thyroid Eye Disease (TED). The offering was priced at an 8.4% discount. https://investors.viridiantherapeutics.com/news/news-details/2025/Viridian-Therapeutics-Announces-Pricing-of-251-Million-Public-Offering-of-Shares-of-Common-Stock/default.aspx
0 · Reply
Butch44
Butch44 Oct. 22 at 3:59 PM
$VRDN don't understand this after the financing deal. ...
1 · Reply
Bondra
Bondra Oct. 22 at 2:48 PM
$VRDN So tempting to sell my CRNX for this gem (now flush with cash 💰)
0 · Reply
aliliimr
aliliimr Oct. 22 at 2:47 PM
$VRDN was waiting for buyout but got this 😀 out for now but will get back if it gets at 19.5 as that was my average :)
0 · Reply
Tdorsey1776
Tdorsey1776 Oct. 22 at 2:04 PM
$VRDN There's a ludicrous amount of money sloshing around
0 · Reply
CDMO
CDMO Oct. 22 at 1:50 PM
$VRDN perfect timing 🫡@CH_Expat
1 · Reply
DonCorleone77
DonCorleone77 Oct. 22 at 12:50 PM
$VRDN Viridian Therapeutics 11.425M share Spot Secondary priced at $22.00
0 · Reply
Pika_Capital
Pika_Capital Oct. 21 at 9:57 PM
$VRDN lol. Offering after recent financial deal. Someone must be wanting to buy tons of shares or these guys just want to sit on huge pile of cash regardless. Tomorrow should be interesting
1 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 1:33 PM
Oppenheimer has adjusted their stance on Viridian Therapeutics ( $VRDN ), setting the rating to Outperform with a target price of 32 → 36.
0 · Reply
Quantumup
Quantumup Oct. 21 at 12:18 PM
H.C. Wainwright reiterated $VRDN Buy/$34 $DHTRF $RHHBY H.C. Wainwright said in its note:
0 · Reply
CDMO
CDMO Oct. 20 at 7:34 PM
$VRDN sold. Was debating myself whether to wait for vrdn006 data, but wont do that. GL all. Might be back below 20 if that happens
0 · Reply
Pika_Capital
Pika_Capital Oct. 20 at 1:03 PM
$VRDN not a bad deal honestly. They avoided dilution but gave up on a bit of future profits
1 · Reply
Tdorsey1776
Tdorsey1776 Oct. 20 at 12:44 PM
$VRDN DRI terms: The Company will pay tiered royalties to DRI based on net sales of veligrotug, VRDN-003 and certain other related products (the “net sales”). The royalties consist of (i) 7.5% of annual U.S. net sales up to and including $600 million, which royalties could increase to low-double digits if marketing approval for VRDN-003 is not received prior to a specified date, (ii) 0.8% of annual U.S. net sales above $600 million and up to and including $900 million, (iii) 0.25% of annual U.S. net sales above $900 million and up to $2.X billion, and (iv) no royalty owed for annual U.S. net sales in excess of $2.X billion
0 · Reply
Tdorsey1776
Tdorsey1776 Oct. 20 at 12:40 PM
$VRDN Not sure I love this DRI transaction but I do like the accelerated timelines: "....today announced it entered into a royalty financing agreement with DRI Healthcare Acquisitions LP (DRI) and accelerated its timelines for the submission of the veligrotug BLA and the topline clinical data readouts of its VRDN-003 REVEAL trials in patients with thyroid eye disease (TED)."
0 · Reply
Tdorsey1776
Tdorsey1776 Oct. 20 at 12:38 PM
$VRDN Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million - Viridian receives $55 million upfront and potential near-term milestones up to $115 million based on positive VRDN-003 topline data and U.S. veligrotug marketing approval - - Upfront and anticipated near-term milestones together with existing cash expected to fully fund the commercial launches of both veligrotug and VRDN-003 - - Veligrotug Biologics License Application (BLA) submission expected imminently; VRDN-003 phase 3 clinical trial topline data readouts now expected Q1 2026 for REVEAL-1 and Q2 2026 for REVEAL-2 - - Amended credit facility with Hercules Capital, Inc., providing additional access to capital at the company’s discretion based on milestone achievements -
0 · Reply
CDMO
CDMO Oct. 17 at 7:47 PM
$IDYA and $VRDN are doing surprisingly well in an ugly market today
0 · Reply
Quantumup
Quantumup Oct. 17 at 7:14 PM
Jefferies reiterated $VRDN at a Buy-$44, and said that $RHHBY's results remove key comp pressure and position '003 as the leading Q4W+ SubQ therapy for TED after Roche's mixed Phase 3 results for its IL-6mAb Satralizumab in thyroid eye diseases—one pivotal trial didn't hit the primary endpoint while the other showed efficacy meaningfully weaker than $VRDN's Veligrotug.
0 · Reply
Tdorsey1776
Tdorsey1776 Oct. 17 at 7:13 PM
$VRDN Its not too late to jump on the VRDN train to $40+. Veligrotug is a better option with superior treatment profile compared to Tepezza especially in Chronic TED which represents 75% of the TED TAM. Veligrotug showed a significantly higher proptosis responder rate (70% vs 5%) and mean proptosis reduction (2.9mm vs 0.5mm) and Veligrotug demonstrated a higher rate of complete diplopia resolution. Even though the FDA revised the original Tepezza label to include Chronic because there was no other real option, Tep sales have been stagnant I suspect because Docs know the clinical data showed not real benefit....P4 data was decent.....but Veligrotug is superior.
0 · Reply
Tdorsey1776
Tdorsey1776 Oct. 17 at 6:50 PM
$VRDN Veligrotug will dominate TED...both active and chronic. Who wants to own the franchise and pipeline. Its a steal under $40
0 · Reply
notreload_ai
notreload_ai Oct. 17 at 6:39 PM
Jefferies and Wedbush maintain Buy ratings on $VRDN as Roche's thyroid eye disease drug shows weaker results than Viridian's veligrotug therapy. https://notreload.xyz/viridian-therapeutics-gets-buy-ratings-roche-fails/
0 · Reply
CDMO
CDMO Oct. 17 at 3:52 PM
$VRDN something brewin
0 · Reply